199 related articles for article (PubMed ID: 12374277)
1. The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy.
Eiben GL; Velders MP; Kast WM
Adv Cancer Res; 2002; 86():113-48. PubMed ID: 12374277
[No Abstract] [Full Text] [Related]
2. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
[TBL] [Abstract][Full Text] [Related]
3. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.
Yang R; Wheeler CM; Chen X; Uematsu S; Takeda K; Akira S; Pastrana DV; Viscidi RP; Roden RB
J Virol; 2005 Jun; 79(11):6741-50. PubMed ID: 15890912
[TBL] [Abstract][Full Text] [Related]
4. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide.
Jochmus I; Osen W; Altmann A; Buck G; Hofmann B; Schneider A; Gissmann L; Rammensee HG
J Gen Virol; 1997 Jul; 78 ( Pt 7)():1689-95. PubMed ID: 9225046
[TBL] [Abstract][Full Text] [Related]
5. Immunology of human papillomavirus infection in lower genital tract neoplasia.
Man S; Fiander A
Best Pract Res Clin Obstet Gynaecol; 2001 Oct; 15(5):701-14. PubMed ID: 11563868
[TBL] [Abstract][Full Text] [Related]
6. Clinical studies of human papilloma vaccines in cervical cancer.
Adams M; Borysiewicz L; Fiander A; Man S; Jasani B; Navabi H; Evans AS; Mason M
Adv Exp Med Biol; 2001; 495():419-27. PubMed ID: 11774604
[No Abstract] [Full Text] [Related]
7. Therapeutic potential of protein and adjuvant vaccinations on tumour growth.
Gérard CM; Baudson N; Kraemer K; Bruck C; Garçon N; Paterson Y; Pan ZK; Pardoll D
Vaccine; 2001 Mar; 19(17-19):2583-9. PubMed ID: 11257396
[TBL] [Abstract][Full Text] [Related]
8. [The role of human papillomavirus in carcinogenesis of cervical cancer and vaccination for HPV].
Kariya M; Fujii S
Uirusu; 2002 Dec; 52(2):287-93. PubMed ID: 12685321
[No Abstract] [Full Text] [Related]
9. Immune evasion in human papillomavirus-associated cervical cancer.
Tindle RW
Nat Rev Cancer; 2002 Jan; 2(1):59-65. PubMed ID: 11902586
[TBL] [Abstract][Full Text] [Related]
10. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
[TBL] [Abstract][Full Text] [Related]
11. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
[TBL] [Abstract][Full Text] [Related]
12. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus in carcinogenesis of cervical cancer.
de Silva NR; Mendis L; Perera N
Ceylon Med J; 1999 Mar; 44(1):45-7. PubMed ID: 10643100
[No Abstract] [Full Text] [Related]
15. Origin and immunoescape of uterine cervical cancer.
Van Hede D; Langers I; Delvenne P; Jacobs N
Presse Med; 2014 Dec; 43(12 Pt 2):e413-21. PubMed ID: 25448124
[TBL] [Abstract][Full Text] [Related]
16. Association between human papillomavirus 16 E6 variants and human leukocyte antigen class I polymorphism in cervical cancer of Swedish women.
Zehbe I; Mytilineos J; Wikström I; Henriksen R; Edler L; Tommasino M
Hum Immunol; 2003 May; 64(5):538-42. PubMed ID: 12691704
[TBL] [Abstract][Full Text] [Related]
17. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
[TBL] [Abstract][Full Text] [Related]
18. Immunity to oncogenic human papillomaviruses.
Konya J; Dillner J
Adv Cancer Res; 2001; 82():205-38. PubMed ID: 11447764
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
[TBL] [Abstract][Full Text] [Related]
20. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses.
Rocha-Zavaleta L; Alejandre JE; Garcia-Carranca A
J Med Virol; 2002 Jan; 66(1):86-95. PubMed ID: 11748663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
